Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now directly owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Collegium Pharmaceutical Price Performance
Shares of COLL stock opened at $33.18 on Wednesday. The firm has a fifty day simple moving average of $30.57 and a 200-day simple moving average of $34.10. The company has a market capitalization of $1.07 billion, a PE ratio of 14.30 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a twelve month low of $28.39 and a twelve month high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.
Wall Street Analysts Forecast Growth
COLL has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Friday, January 10th. Piper Sandler reissued a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $43.80.
Hedge Funds Weigh In On Collegium Pharmaceutical
A number of institutional investors have recently added to or reduced their stakes in COLL. Pacer Advisors Inc. grew its stake in shares of Collegium Pharmaceutical by 31.8% during the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after acquiring an additional 821,541 shares in the last quarter. Rubric Capital Management LP boosted its holdings in Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after purchasing an additional 499,473 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after purchasing an additional 215,874 shares during the last quarter. Emerald Advisers LLC increased its holdings in Collegium Pharmaceutical by 27.2% during the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after purchasing an additional 177,129 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares in the last quarter.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Featured Stories
- Five stocks we like better than Collegium Pharmaceutical
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What Are Dividend Champions? How to Invest in the Champions
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What Are Treasury Bonds?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.